Hybrid cytokines as hematopoietic growth factors.
A large body of in vitro and in vivo data suggests that combinations of cytokines provide the most effective mechanism for stimulating multilineage acceleration of hematopoiesis. Creation of a granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3) fusion protein has yielded a single therapeutic which has enhanced biological activity in comparison to the individual cytokines from which it is composed. In vivo studies with this fusion protein (PIXY321) suggest that it may provide a means to accelerate both neutrophil and platelet recovery in clinical settings in which hematopoiesis is suppressed. The biology of PIXY321 and the potential for other fusion proteins is discussed.
Williams
D E
DE
Immunex Research and Development Corporation, Seattle, Washington.
Park
L S
LS
Broxmeyer
H E
HE
Lu
L
L
D004338:Drug Combinations; D015195:Drug Design; D004357:Drug Synergism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007377:Interleukin-3 / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*
D004338:Drug Combinations; D007377:Interleukin-3; D011993:Recombinant Fusion Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor